Outlook Therapeutics (OTLK) Free Cash Flow (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Free Cash Flow of -$7.8 million for Q1 2026, up 52.8% year-over-year from -$5.1 million in Q1 2025, and up 47.6% quarter-over-quarter from -$14.9 million in Q4 2025.
Outlook Therapeutics (OTLK) Free Cash Flow (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Free Cash Flow for 12 consecutive years, with -$7.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 52.8% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at -$47.0 million (up 26.54% YoY), while the FY2025 annual figure was -$51.9 million, up 24.53% from the prior year.
- Free Cash Flow advanced to -$7.8 million in Q1 2026 per OTLK's latest filing, from -$14.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$7.8 million in Q1 2026 and bottomed at -$21.1 million in Q2 2022.
- Historically, Free Cash Flow has averaged -$13.6 million across 5 years, with a median of -$13.0 million in 2023.
- Annual changes were most pronounced in 2024 — Free Cash Flow slumped 137.44% — and 2026, when it jumped 52.8%.
- Outlook Therapeutics' Free Cash Flow stood at -$8.9 million in 2022, then sank by 46.41% to -$13.0 million in 2023, then grew by 15.84% to -$11.0 million in 2024, then tumbled by 36.21% to -$14.9 million in 2025, then surged by 47.6% to -$7.8 million in 2026.
- Business Quant data shows OTLK's Free Cash Flow at -$7.8 million in Q1 2026, -$14.9 million in Q4 2025, and -$12.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | -21.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.83 Mn |
| Mar 31, 2026 | -7.83 Mn |
| Dec 31, 2025 | -14.94 Mn |
| Dec 31, 2025 | -14.94 Mn |
| Sep 30, 2025 | -12.38 Mn |
| Sep 30, 2025 | -12.38 Mn |
| Jun 30, 2025 | -11.90 Mn |
| Jun 30, 2025 | -11.90 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Sep 30, 2024 | -16.96 Mn |
| Sep 30, 2024 | -16.96 Mn |
| Jun 30, 2024 | -19.54 Mn |
| Jun 30, 2024 | -19.54 Mn |
| Mar 31, 2024 | -19.27 Mn |
| Mar 31, 2024 | -19.27 Mn |
| Dec 31, 2023 | -13.03 Mn |
| Dec 31, 2023 | -13.03 Mn |